Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

Inclusion Criteria:

All subjects must meet the following criteria:

* Subject must have incurable metastatic colorectal cancer with metastatic disease to the liver
* Subject must have extrahepatic metastatic disease, as confirmed by radiographic evidence or surgical/other documentation that cannot be treated by surgery or image guided therapy to an endpoint of no evidence of residual disease by imaging criteria
* Subject has received and, in the opinion of the treating physician, progressed through at least one prior chemotherapy regimen for metastatic disease, or has developed recurrent disease on or within 6 months of completing adjuvant therapy
* At least 50% of the total tumor burden is in the liver, as determined by the treating investigator, and prior to any study specified intervention (resection or ablation).
* Subject must have no more than 10 hepatic tumors remaining after surgical resection, with no tumor exhibiting a unidimensional size greater than 5cm
* Subject is medically eligible to receive RFA, as determined by the treating investigator
* Subject is naïve to, and medically eligible (as defined by the treating investigator) to receive, at least one of the following:
* an oxaliplatin containing regimen
* an irinotecan containing regimen
* an anti-EGFR monoclonal antibody-containing regimen (subject must be naïve to both cetuximab and panitumumab)
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
* Age \> 18 years
* Subject life expectancy \> 3 months
* International Normalized Ratio (INR) \< 2.0
* Platelets \> 100 x103/mm3
* Total Bilirubin \<1.5mg/dl
* Creatinine level \< 2.0 mg/dl
* Must sign an Informed Consent form

Exclusion Criteria:

All subjects who meet any of the following criteria will not be enrolled into the study:

* Subjects's extrahepatic disease is amenable to curative surgical or image guided therapy
* Subject has known brain metastases
* Uncorrectable coagulopathy
* Subject is pregnant, nursing, or wishes to become pregnant during the study
* Other serious medical condition(s) (e.g. uncontrolled infection, uncontrolled cardiac disease) that, in the opinion of the treating investigator, would preclude study treatment or impact survival.
* Current or planned treatment with any experimental chemotherapy or biological agents